ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Gastrointestinal Cancer

Gastrointestinal Cancer

Lymph node status after undergoing neoadjuvant chemotherapy and resection of esophagogastric cancer was the only independent predictor of survival.

A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.

The USPSTF has issued an updated guideline with recommendations regarding screening for colorectal cancer. A systematic review found that screening can be of “substantial net benefit.”

Here we discuss the evolution of standard therapy for rectal cancer patients and the use of preoperative CRT for the treatment of locally advanced disease. Treatment schemes that have attempted to broaden the horizons of standard therapy include the use of induction chemotherapy and “watch-and-wait” approaches.

By adjusting the sequencing of currently available treatments, improved compliance with therapy is ensured, and novel scientific and clinically relevant hypotheses can be further explored.

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.

In this interview we discuss the CheckMate 142 trial, which looked at nivolumab and ipilimumab for the treatment of metastatic colorectal cancer.

Pages

Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.